Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in adult Langerhans Cell Histiocytosis
NCT03270020Phase 2Completed
- Sponsor
- Hellenic Society for the Study of Bone Metabolism
- Start
- Sep 2017
- Primary completion
- Jun 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of denosumab in Langerhans cell histiocytosis (LCH), sponsored by Hellenic Society for the Study of Bone Metabolism. Primary endpoint: Incidence of patients with active disease at 8 months. Started Sep 2017; status: completed.
02
Drugs
denosumab
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT03270020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03270020.